mefloquine (Lariam)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Lariam.

Indications

Contraindications

pregnancy category = c

pregnancy category = +

safety in lactation = ?

Dosage

Tabs: 250 mg.

Pharmacokinetics

elimination via liver

1/2life = 2-3 weeks

protein binding = 98 %

Adverse effects

Drug interactions

Laboratory

More general terms

Additional terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1175
  3. Medical Knowledge Self Assessment Program (MKSAP) 11, 16. American College of Physicians, Philadelphia 1998, 2012
  4. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  5. 5.0 5.1 Prescriber's Letter 9(7):40 2002 Prescriber's Letter 9(10):57 2002
  6. 6.0 6.1 Aarnoudse ALHJ et al, MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006, 80:367 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17015054
  7. Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev. 2008 Jul;21(3):466-72 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18625682
  8. 8.0 8.1 FDA MedWatch. July 29, 2013 Mefloquine Hydrochloride: Drug Safety Communication - Label Changes Due To Risk of Serious Psychiatric and Nerve Side Effects. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm362887.htm
  9. 9.0 9.1 Deprecated Reference

Database